All Stories

AstraZeneca, Daiichi unblind Enhertu study early as star ADC helps stomach cancer patients live longer

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer, the partners said on Monday.

Mar 3, 2025 - 21:53
 0
AstraZeneca, Daiichi unblind Enhertu study early as star ADC helps stomach cancer patients live longer
AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer, the partners said on Monday.
Read More

Tags:

Previous Article

Emirates Bets on Cambodia as Chinese Travelers Stay Away

Next Article

STAT+: Top HHS spokesman abruptly resigns after reports of tensions with RFK Jr....

Related Posts

It’s official: Senate votes to confirm RFK Jr. as HHS secretary

It’s official: Senate votes to confirm RFK Jr. as HHS s...

Feb 13, 2025  0

Bristol Myers combo follows Roche, AstraZeneca immunotherapy rivals into first-line liver cancer

Bristol Myers combo follows Roche, AstraZeneca immunoth...

Apr 11, 2025  0

As FDA's Peter Marks resigns, industry watchers eye vaccine, cell and gene therapy hits

As FDA's Peter Marks resigns, industry watchers eye vac...

Mar 31, 2025  0